Are You Thinking About Investing In Eli Lilly and Company?

Large-cap Health Care company Eli Lilly and Company has logged a 1.1% change today on a trading volume of 1,256,926. The average volume for the stock is 3,296,819.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Based in Indianapolis, United States the company has 39,000 full time employees and a market cap of $592,851,697,664. Eli Lilly and Company currently offers its equity investors a dividend that yields 0.7% per year.

The company is now trading -1.76% away from its average analyst target price of $635.67 per share. The 25 analysts following the stock have set target prices ranging from $430.0 to $727.0, and on average give Eli Lilly and Company a rating of buy.

Over the last 52 weeks, LLY stock has risen 72.1%, which amounts to a 48.6% difference compared to the S&P 500. The stock's 52 week high is $631.37 whereas its 52 week low is $309.2 per share. Based on Eli Lilly and Company's average net margin growth of 0.6% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 32,072,500 4,988,400 16 -27.27
2022 28,541,400 6,244,800 22 10.0
2021 28,318,400 5,581,700 20 -20.0
2020 24,539,800 6,193,700 25 -32.43
2019 22,319,500 8,318,400 37 146.67
2018 21,493,300 3,232,000 15
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.